NCT03917069 is a Phase 2 clinical trial of Chemotherapeutic Combinations in Advanced Melanoma, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT03917069?

NCT03917069 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT03917069?

Interventions in NCT03917069: Chemotherapeutic Combinations, chemotherapy.

What condition does NCT03917069 study?

NCT03917069 studies Advanced Melanoma.

Is NCT03917069 still recruiting?

NCT03917069 is currently status unknown. Last updated 17 April 2019.

Last reviewed 2019-04-17 · How we verify

NCT03917069

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Status unknown Phase 2 Last updated 17 April 2019

What this trial tests

Phase 2 trial testing Chemotherapeutic Combinations in Advanced Melanoma in 145 participants. Status unknown.

Timeline

23 March 2019

Primary endpoint
30 September 2021

30 September 2022

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	145
Start date	23 March 2019
Primary completion	30 September 2021
Estimated completion	30 September 2022
Sites	1 location across China

Drugs / interventions tested

Chemotherapeutic Combinations — full drug profile →
chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Advanced Melanoma — all drugs for Advanced Melanoma →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 70, any sex, with Advanced Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin * Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin * endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Melanoma Management: From Epidemiology to Treatment and Latest Advances.
Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. · · 2022 · cited 98× · PMID 36230575 · DOI 10.3390/cancers14194652
How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT.
Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. · · 2022 · cited 22× · PMID 36145569 · DOI 10.3390/pharmaceutics14091817

Verify or expand the search:

Other trials of Chemotherapeutic Combinations

Trials testing the same drug.

NCT07355764 — MA-CRC-II-016 SHR-1811 · Phase 2 · not yet recruiting
NCT03254511 — Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer · Phase 2 · unknown

Other recruiting trials for Advanced Melanoma

Currently open trials in the same condition.

NCT07310784 — A Phase II Trial of LM103 in Advanced Melanoma · Phase 2 · recruiting
NCT07099430 — A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma · Phase 1, PHASE2 · recruiting
NCT05629546 — Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on C · Phase 1 · recruiting
NCT06264180 — VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] · Phase 3 · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03917069 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 17 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917069.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing